Coronary artery disease risk factors in patients with schizophrenia: effects of short term antipsychotic treatment.
about
Late-onset schizophrenia: do recent studies support categorizing LOS as a subtype of schizophrenia?Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effectsElevated C-reactive protein associated with late- and very-late-onset schizophrenia in the general population: a prospective studyTranslating potential biomarker candidates for schizophrenia and depression to animal models of psychiatric disorders.Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients.Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysis.A significant causal association between C-reactive protein levels and schizophreniaNovel therapeutic targets in depression and anxiety: antioxidants as a candidate treatment.The multidimensional nature of metabolic syndrome in schizophrenia: lessons from studies of one-carbon metabolism and DNA methylation.Genetic association of ACSM1 variation with schizophrenia and major depressive disorder in the Han Chinese population.Evaluation of Paraoxonase, Arylesterase and Malondialdehyde Levels in Schizophrenia Patients Taking Typical, Atypical and Combined Antipsychotic TreatmentAssociation between C-reactive protein and risk of schizophrenia: An updated meta-analysis.Association between antipsychotic treatment and leptin levels across multiple psychiatric populations: An updated meta-analysis.High-density lipoprotein-associated paraoxonase-1 activity for prediction of adverse outcomes in outpatients with chronic heart failure.Genotype-phenotype Analysis of Paraoxonase 1 in Schizophrenic Patients Treated with Atypical Antipsychotics.C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications.
P2860
Q26827995-AD32D25A-B365-46A7-B65D-A34F0F849AB7Q28657600-FE56511C-5723-485E-8F80-4C784E9524BEQ34048554-3E2FB633-22B1-48BA-BCE5-82A5D1EFD12CQ34214660-732972C8-47B1-4505-8ACF-13DD5E4A7B76Q34484974-1F63A292-1492-4AC7-BAF1-D18E9868177BQ35566086-19310DC5-AC11-49EB-A99A-AA657A7617E8Q36914697-413E8908-DA3A-4D58-9D2F-60A5FFDE2252Q37661357-F7C36480-CDD9-4A1C-ACA1-587206CD3057Q38113237-520B0CBA-324C-4C73-AF34-557A722541F5Q41471577-54E6B397-F46C-42D0-8BAD-EC5AB32137F3Q41602246-8DA14108-29B3-4E26-9281-70BB1FE114E4Q43213613-E4EC84FC-E0EC-4C9A-B4DA-654ACCAFE92EQ47605999-485AC762-2D7D-4516-8BCE-980B277CA9E5Q47980523-AE317853-CBA3-450C-B385-631ECC522728Q49348776-ED772163-CCD3-41FA-BB51-A93349001135Q50578956-2FEAD3BD-F674-4A83-8B8C-FCF555A67AD0
P2860
Coronary artery disease risk factors in patients with schizophrenia: effects of short term antipsychotic treatment.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Coronary artery disease risk f ...... term antipsychotic treatment.
@en
Coronary artery disease risk f ...... term antipsychotic treatment.
@nl
type
label
Coronary artery disease risk f ...... term antipsychotic treatment.
@en
Coronary artery disease risk f ...... term antipsychotic treatment.
@nl
prefLabel
Coronary artery disease risk f ...... term antipsychotic treatment.
@en
Coronary artery disease risk f ...... term antipsychotic treatment.
@nl
P2093
P2860
P356
P1476
Coronary artery disease risk f ...... term antipsychotic treatment.
@en
P2093
Asli Sarandol
Cengiz Akkaya
Emre Sarandol
Nihal Ocak
Selcuk Kirli
P2860
P304
P356
10.1177/0269881107077609
P407
P577
2007-08-22T00:00:00Z